Skip to main content

Cerebrolysin vs Pinealon

Both Cerebrolysin and Pinealon are used for cognitive. Here's how their evidence, dosing, and regulatory status actually compare.

Cerebrolysin

Evidence B

Cerebrolysin (porcine brain peptide complex)

A standardized mixture of low-molecular-weight peptides from porcine brain. Decades of stroke, dementia, and TBI trial data — modest but consistent cognitive recovery effects.

View full Cerebrolysin profile →

Pinealon

Evidence C

Pinealon (EDR)

A short tripeptide developed in Russia for cognitive aging and oxidative stress. Limited Western clinical evidence.

View full Pinealon profile →

Side-by-Side

AttributeCerebrolysinPinealon
Evidence GradeBC
FDA StatusNot FDA-approved in US — approved in 50+ countries for stroke, traumatic brain injury, and dementiaNot FDA-approved — Russian-origin research peptide
Typical DoseTrial range: 5–30 mL daily (intravenous infusion)5–10 mg daily for 10–20 days (subcutaneous, cycled)
Clinics Indexed419
Categoriescognitive, neuroprotectioncognitive, longevity

Key reported benefits — Cerebrolysin

  • Stroke recovery support
  • TBI rehabilitation
  • Cognitive function in dementia

Key reported benefits — Pinealon

  • Cognitive function (preclinical)
  • Reduced oxidative damage
  • Sleep/circadian effects

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons